We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Genetic Factors Involved in Sudden Unexpected Death in Children

By LabMedica International staff writers
Posted on 29 Apr 2021
Print article
Image: New genetic factors involved in Sudden Unexpected Death in Pediatrics (SUDP) have been revealed by combining exome sequencing analysis with detailed phenotyping (Photo courtesy of Boston Children`s Hospital)
Image: New genetic factors involved in Sudden Unexpected Death in Pediatrics (SUDP) have been revealed by combining exome sequencing analysis with detailed phenotyping (Photo courtesy of Boston Children`s Hospital)
About 10% of deaths in infants and children occur suddenly and have no apparent cause. Sudden Unexpected Death in Pediatrics (SUDP) encompasses several related phenomena, including Sudden Infant Death Syndrome (SIDS), Sudden Unexplained Death in Childhood (SUDC), and Sudden Unexpected Infant Death (SUID).

The most widely accepted explanation for these unexplained deaths, is that children with an intrinsic, or genetic, predisposition experience some sort of extrinsic risk, such as soft bedding or a certain sleep position, during a critical period of their development. A new study has found several genes with functions in neurological disease or systemic/syndromic conditions that had not previously been implicated in the SUDP.

Medical Scientists at the Boston Children's Hospital (Boston, MA, USA) and their colleagues surveyed a total of 352 SUDP cases, including 73 with parental samples. The age of death in these children ranged from one day to 11 years, with an average of six months, and the team obtained detailed phenotypic descriptions for them. The investigators conducted exome sequencing and analyzed the data for rare damaging variants in genes involved in neurological, cardiac, and systemic or syndromic disease mechanisms, a list of 294 potential SUDP genes. They classified variants as pathogenic, likely pathogenic, and variants of uncertain significance (VUS) and introduced an additional category, called VUS-favor pathogenic (VUS-FP).

In a proband-only analysis, they identified 109 rare damaging variants in 98 probands, or 28% of which 12 were classified as pathogenic or likely pathogenic and 17 as VUS-FP. This was a higher burden of such variants than in healthy controls. In addition, an analysis of the parent-proband exome data uncovered 51 de novo variants, of which eight were classified as pathogenic/likely pathogenic or VUS-FP, as well as 13 X-linked maternally inherited variants. A burden analysis found that SUDP trios had almost three times more rare damaging de novo variants than controls, suggesting that these variants play a causal role.

Overall, the scientists identified 38 rare damaging variants, 16 pathogenic or likely pathogenic and 22 VUS-FP variants in the SUDP cases, accounting for 11% of all cases. Of those, 14 were in neurological, 18 in cardiac, and six in systemic/syndromic disease genes. Variants in cardiac disease genes all occurred in children who died within their first year of life.

The authors concluded that their results suggest that genetic factors play an important role in SUDP. The findings can provide bereaved parents with an explanation of why their child died, help identify at-risk family members, and lead to counseling about recurrence risk. The study was presented at the American College of Medical Genetics and Genomics annual clinical meeting held virtually on 13-16 April, 2021.

Related Links:
Boston Children's Hospital

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more